IKT Inhibikase Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: IKT

Price (delayed)

$1.39

Market cap

$9M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.57

Enterprise value

$369,513

Inhibikase is a clinical-stage pharmaceutical company developing therapeutics for Parkinson's disease and related disorders that arise inside and outside of the brain. Inhibikase is headquartered in Atlanta, Georgia with additional ...

Highlights
The EPS has grown by 17% YoY and by 10% from the previous quarter
The revenue has soared by 111% YoY but it has decreased by 20% from the previous quarter
Inhibikase Therapeutics's gross profit has soared by 111% YoY but it has decreased by 20% from the previous quarter
The company's debt has surged by 97% QoQ
The equity has declined by 48% year-on-year and by 27% since the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.inhibikase.com
Peers: OMER OMGA

Key stats

What are the main financial stats of IKT
Market
Shares outstanding
6.48M
Market cap
$9M
Enterprise value
$369,513
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.78
Price to sales (P/S)
28.46
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.42
Earnings
Revenue
$260,501
EBIT
-$19.03M
EBITDA
-$18.85M
Free cash flow
-$18.1M
Per share
EPS
-$3.57
Free cash flow per share
-$3.39
Book value per share
$1.78
Revenue per share
$0.05
TBVPS
$2.72
Balance sheet
Total assets
$14.51M
Total liabilities
$3.53M
Debt
$531,879
Equity
$10.98M
Working capital
$10.77M
Liquidity
Debt to equity
0.05
Current ratio
4.13
Quick ratio
3.85
Net debt/EBITDA
0.46
Margins
EBITDA margin
-7,236.6%
Gross margin
100%
Net margin
-7,304.7%
Operating margin
-7,712%
Efficiency
Return on assets
-91.8%
Return on equity
-107.5%
Return on invested capital
-177.6%
Return on capital employed
-171.9%
Return on sales
-7,304.7%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

IKT stock price

How has the Inhibikase Therapeutics stock price performed over time
Intraday
3.73%
1 week
-18.24%
1 month
-35.35%
1 year
-92.73%
YTD
9.45%
QTD
-35.65%

Financial performance

How have Inhibikase Therapeutics's revenue and profit performed over time
Revenue
$260,501
Gross profit
$260,501
Operating income
-$20.09M
Net income
-$19.03M
Gross margin
100%
Net margin
-7,304.7%
The revenue has soared by 111% YoY but it has decreased by 20% from the previous quarter
Inhibikase Therapeutics's gross profit has soared by 111% YoY but it has decreased by 20% from the previous quarter
The company's net margin has surged by 50% YoY but it fell by 24% QoQ
IKT's operating margin is up by 47% year-on-year but it is down by 25% since the previous quarter

Growth

What is Inhibikase Therapeutics's growth rate over time

Valuation

What is Inhibikase Therapeutics stock price valuation
P/E
N/A
P/B
0.78
P/S
28.46
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.42
The EPS has grown by 17% YoY and by 10% from the previous quarter
The equity has declined by 48% year-on-year and by 27% since the previous quarter
The stock's price to book (P/B) is 11% more than its last 4 quarters average of 0.7
The revenue has soared by 111% YoY but it has decreased by 20% from the previous quarter
IKT's P/S is 55% below its last 4 quarters average of 62.8

Efficiency

How efficient is Inhibikase Therapeutics business performance
IKT's return on equity has dropped by 63% year-on-year and by 14% since the previous quarter
The return on assets has dropped by 60% year-on-year and by 12% since the previous quarter
The ROS has soared by 50% YoY but it has contracted by 20% from the previous quarter
IKT's return on invested capital is up by 29% year-on-year but it is down by 23% since the previous quarter

Dividends

What is IKT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for IKT.

Financial health

How did Inhibikase Therapeutics financials performed over time
The total assets has declined by 42% year-on-year and by 19% since the previous quarter
IKT's quick ratio is down by 38% year-on-year and by 37% since the previous quarter
The company's debt is 95% lower than its equity
The debt to equity has surged by 150% since the previous quarter
The company's debt has surged by 97% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.